


DOCKET NO.: ISHT-1004 (HTS-0016US.P1)**PATENT****REMARKS**

Claims 1-53 were pending. Upon entry of this amendment, claims 1-8, 13-19, 23-28 and 44-68 will be pending. Claim 1 is amended herein to specify that the antisense compound is targeted to a nucleic acid molecule encoding kinesin-like 1 with SEQ ID NO: 3 and the compound comprises at least an 8-nucleobase portion of SEQ ID NO: 86, 96, 116 or 122. Claim 1 is further amended to specify that the compound is "specifically hybridizable" with a nucleic acid molecule encoding kinesin-like 1. Basis for these amendments can be found throughout the specification and claims as originally filed, such as, for example, pages 7-8, 13-14 and 87-91 of the specification. Claims 50 and 51 are amended herein for clarity. New claims 54-68 find basis throughout the specification and claims as originally filed. Thus, no new matter has been added.

An early Office Action on the merits is earnestly solicited. The Examiner is invited to contact Applicants' undersigned representative at the number below if there are any questions regarding Applicants' claimed invention.

Respectfully submitted,


Jodi L. Connolly, Ph.D.
Registration No. 54,044

Date: September 20, 2005

ISIS Pharmaceuticals, Inc.
1896 Rutherford Rd.
Carlsbad, CA 92008
Telephone: (760) 931-9200
Facsimile: (760) 603-3820